How At-risk Mental State Is Linked to Psychosis

Article

British researchers have determined the factors that lead patients with an ARMS to develop psychosis.

British researchers, aiming to determine what predicts the transition in many people with an at-risk mental state (ARMS), have determined the presenting symptoms that do so and report their results in the August 12 advance access edition of Schizophrenia Bulletin.

Investigating psychopathological dimension in 122 participants who met Personal Assessment and Crisis Evaluation cliniccriteria for the ARMS, the team examined “whether particularsymptom dimensions predicted subsequent transition to psychosis.” Specifically, a “principal axis factor analysis was performed on symptom scores,obtained at presentation from the Comprehensive Assessment ofthe At-Risk Mental State, using Varimax rotation. The relationshipbetween dimension scores and transition to psychosis duringthe following 24 months was then examined employing Cox regressionanalysis.”

The researchers found that ARMS symptoms have a dimensional structure—negative, anxiety, disorganization/cognitive, self-harm, and maniac symptom dimensions—similar to that seen in patients with schizophrenia, aside from the positive symptom dimension. They concluded that the “association betweenscores on the disorganization/cognitive and negative dimensionsand later transition is consistent with independent evidencethat formal thought disorder, subjective cognitive impairments,and negative symptoms are linked to the subsequent onset ofpsychosis.”

More on At-risk Mental State:

  • Access the full article in Schizophrenia Bulletin
  • Instructions for patients, or loved ones, on when to intervene
  • Neural Correlates of Movement Generation in the 'At-risk Mental State'
Related Videos
Insight on the Promising 52-Week KarXT Data with Rishi Kakar, MD
Sunny Rai, PhD: “I” Language Markers Do Not Detect Depression in Black Individuals
Rebecca A. Andrews, MD: Issues and Steps to Improve MDD Performance Measures
A Voice Detecting Depression? Lindsey Venesky, PhD, Discusses New Data
Daniel Karlin, MD: FDA Grants Breakthrough Designation to MM120 for Anxiety
Leesha Ellis-Cox: Steps to Closing the Bipolar Disorder Diagnosis Gap for Blacks
Daniel Greer, PharmD: Reduction in Rehospitalizations with Antipsychotic Injections for Schizophrenia
© 2024 MJH Life Sciences

All rights reserved.